2023 Sales Guidance Raised Penumbra issued updated guidance for 2023 revenues. The company expects net sales in the range of $1.05-$1.07 billion, implying a 24-26% improvement year over year.

Penumbra is up 26.6% since the beginning of the year, and at $303.76 per share, has set a new 52-week high. Investors who bought $1,000 worth of Penumbra’s shares 5 years ago would now be ...

Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention. Read more on PEN stock here.

Revenue Growth: Penumbra's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.11%.

Penumbra, Inc. (NYSE: PEN) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen ...

News about one of Penumbra 's (PEN 0.53%) development programs and an analyst's price target raise combined to boost the medical device company's stock on Monday. Its price rose by over 4%, giving ...

Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Penumbra (NYSE:PEN) in the last three months.Summarizing their recent assessments, the ...

Sales of $324.1 million, up 16.3% year over year (+16.9% in constant currency) and beating the consensus of $315.66 million. Adjusted EPS of 83 cents, beating the consensus of 67 cents. Revenue ...

Penumbra was founded in 2004 and had $149 million for the year ending in June 30, 2015. Penumbra manufactures nearly all of its products at its 180,000-square-foot Alameda campus.